DMA is a bisbenzimidazole radioprotective agent.1,2 In vivo, DMA (300 mg/kg) decreases radiation-induced lethality without affecting radiation-induced tumor regression in an Ehrlich murine spontaneous adenocarcinoma model.1 It prevents radiation-induced damage of intestinal, hepatic, and splenic tissues, increases in splenic malondialdehyde (MDA) production, and decreases in splenic superoxide dismutase (SOD) activity in a B16/F10 murine melanoma model when administered at a dose of 50 mg/kg.2
1.Nimesh, H., Tiwari, V., Yang, C., et al.Preclinical evaluation of DMA, a bisbenzimidazole, as radioprotector: Toxicity, pharmacokinetics, and biodistribution studies in Balb/c miceMol. Pharmacol.88(4)768-778(2015) 2.Tiwari, V., Kamran, M.Z., Ranan, A., et al.Akt1/NFκB signaling pathway activation by a small molecule DMA confers radioprotection to intestinal epithelium in xenograft modelFree Rad. Biol. Med.108564-574(2017)